SK bioscience Co.,Ltd. (KRX:302440)
South Korea · Delayed Price · Currency is KRW 36,500
-1,250 (-3.31%)
At close: Aug 21, 2026
SK bioscience Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,863,664 | 3,778,446 | 3,948,704 | 5,528,451 | 5,643,627 | 17,212,500 | |
Market Cap Growth | -24.19% | -4.31% | -28.57% | -2.04% | -67.21% | - |
Enterprise Value | 2,835,145 | 3,423,836 | 2,813,918 | 4,326,779 | - | - |
Last Close Price | 36500.00 | 48200.00 | 50400.00 | 72000.00 | 73500.00 | 225000.00 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | 247.72 | 46.09 | 48.47 |
Forward PE | - | 173.78 | 173.78 | 173.78 | 24.69 | 23.37 |
PS Ratio | 4.34 | 5.80 | 14.76 | 14.96 | 12.36 | 18.53 |
PB Ratio | 1.43 | 1.85 | 1.95 | 3.25 | 3.24 | 10.75 |
P/TBV Ratio | 1.77 | 2.27 | 2.34 | 3.27 | 3.25 | 10.78 |
P/FCF Ratio | - | - | - | - | - | 34.87 |
P/OCF Ratio | 641.07 | 36.86 | - | 188.39 | - | 32.08 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.30 | 5.26 | 10.52 | 11.71 | - | - |
EV/EBITDA Ratio | - | - | - | 189.96 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.27 | 0.23 | 0.19 | 0.01 | 0.07 | 0.07 |
Debt / EBITDA Ratio | - | - | - | 0.90 | 0.80 | 0.22 |
Debt / FCF Ratio | - | - | - | - | - | 0.22 |
Net Debt / Equity Ratio | -0.14 | -0.21 | -0.38 | -0.74 | -0.78 | -0.96 |
Net Debt / EBITDA Ratio | 8.75 | 13.43 | 8.58 | -55.04 | -9.61 | -3.12 |
Net Debt / FCF Ratio | 2.15 | 5.41 | 2.62 | 88.81 | 6.91 | -3.12 |
Asset Turnover | 0.23 | 0.23 | 0.11 | 0.19 | 0.22 | - |
Inventory Turnover | 2.73 | 2.88 | 1.63 | 1.70 | 1.35 | - |
Quick Ratio | 2.91 | 3.19 | 4.34 | 9.56 | 4.13 | 3.68 |
Current Ratio | 3.60 | 3.82 | 5.08 | 10.20 | 4.69 | 4.00 |
Return on Equity (ROE) | -4.25% | -2.77% | -2.69% | 1.29% | 7.33% | - |
Return on Assets (ROA) | -2.81% | -2.66% | -3.69% | -0.38% | 3.38% | - |
Return on Invested Capital (ROIC) | -7.75% | -8.64% | -16.21% | -2.91% | 45.57% | 577.65% |
Return on Capital Employed (ROCE) | -5.00% | -4.70% | -5.50% | -0.70% | 6.50% | 28.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -2.96% | -1.52% | -1.36% | 0.40% | 2.17% | 2.06% |
FCF Yield | -4.71% | -2.13% | -7.41% | -0.26% | -3.51% | 2.87% |
Buyback Yield / Dilution | -0.59% | -1.51% | -0.24% | 0.01% | -4.32% | - |